Davion Healthcare Plc filed a Form 6-K on November 9, 2026, disclosing that it entered into a non-exclusive financial advisory agreement with Vienna Capital Partners LLC to support a proposed acquisition financing strategy for 2027.
Key Highlights
- Agreement signed: Davion Healthcare Plc entered into a non-exclusive financial advisory agreement with Vienna Capital Partners LLC, announced via press release on November 6, 2026.
- Financing objective: The company has established an initial aggregate financing objective of US$100 million, with the potential to increase this as its acquisition programme develops.
- Debt focus: The company intends to focus principally on senior secured, non-convertible debt financing from institutional lenders, private credit providers, and other financial institutions.
- Geographic target: Acquisitions are intended to focus principally on established, profitable, and cash-generative businesses in the United States.
- No commitments secured: According to the filing, no binding lender commitments have been secured under the proposed programme, and the US$100 million figure does not represent an established, committed, or currently available credit facility.
Davion Healthcare Outlines 2027 Acquisition Financing Strategy via Vienna Capital Advisory Pact
According to the Form 6-K filed with the U.S. Securities and Exchange Commission, Davion Healthcare Plc (NASDAQ:DAVI) entered into a non-exclusive financial advisory agreement with Vienna Capital Partners LLC on or around November 6, 2026. The agreement is intended to support what the company described as its "proposed acquisition financing strategy for 2027," as stated in the accompanying press release furnished as Exhibit 99.1.
The company disclosed an initial aggregate financing objective of US$100 million, noting that this figure could increase as its acquisition programme develops. The filing specifies that Davion intends to pursue senior secured, non-convertible debt financing from institutional lenders, private credit providers, and other financial institutions. The stated purpose is to fund acquisitions of "established, profitable and cash-generative businesses, principally in the United States."
The filing includes explicit cautionary language, stating that the US$100 million financing objective "is an indicative aggregate target and does not represent an established, committed or currently available credit facility." The filing further notes that "no binding lender commitments have been secured under the proposed programme" and that any future financing will be subject to lender approval, due diligence, definitive documentation, and applicable conditions. The filing states that "there can be no assurance that financing will be obtained in any particular amount or on acceptable terms, or that any proposed acquisition will be completed." The report was signed by Glenn Williams, Chief Executive Officer, on November 9, 2026.
What Was Disclosed
Davion Healthcare Plc reported entering into a non-exclusive financial advisory agreement with Vienna Capital Partners LLC, targeting an initial US$100 million acquisition financing objective for 2027, with no binding commitments yet secured and no guarantee of completion.




Please wait processing your request...